Antimicrobial Breakthrough for Avian Bacterial Infections
The Need: Antimicrobial Breakthrough for Avian Bacterial Infections
Avian species, particularly chickens and turkeys, face significant economic losses due to bacterial infections caused by pathogenic Escherichia coli (APEC) and Salmonella strains (ST and SE). These bacteria not only harm avian populations but also pose serious health risks to humans through contaminated poultry products. Current treatments relying on antimicrobial drugs have limited effectiveness and contribute to the emergence of antibiotic-resistant strains, exacerbating the problem. There is a pressing need for an advanced antimicrobial solution that can effectively combat avian bacterial infections while minimizing the risk of resistance development.
The Technology: Advanced Antimicrobial Peptide Therapy
The technology presents a groundbreaking antimicrobial peptide therapy for treating and preventing bacterial infections in avian species. The composition consists of an antimicrobial peptide, with an amino acid sequence closely resembling specific identified sequences (SEQ ID NO: 21, SEQ ID NO: 32, SEQ ID NO: 85, SEQ ID NO: 86, or SEQ ID NO: 87), or their functional variants. This peptide is administered with a pharmaceutically acceptable carrier to ensure optimal delivery.
In conclusion, the advanced antimicrobial peptide therapy described herein offers a compelling solution to address the commercial need for combating avian bacterial infections caused by pathogenic E. coli (APEC) and Salmonella strains (ST and SE). With its high effectiveness, reduced resistance development, and safety advantages, the technology holds great promise for the poultry industry and public health alike.